Celgene and Boehringer Ingelheim use Medidata clinical trial platform
Medidata a provider of cloud-based solutions for clinical research in life sciences, has recently entered partnering agreements with both Boehringer Ingelheim and Celgene
The pharmaceutical companies will use the Medidata Clinical Cloud, a unified technology platform, for their clinical trials and drug development programmes.
The Clinical Cloud enhances capabilities in data management, study planning and design, trial operations, analytics and patient engagement as well as enabling researchers to conduct faster, more accurate and more cost-effective clinical trials, according to Medidata.
Tarek Sherif, Medidata’s chief executive officer, said: “We are in the early days of a renaissance in drug discovery, and Medidata’s Clinical Cloud is playing a critical role in helping to power the kind of innovation that will improve the lives of patients around the world.”
Klaus Stern, global head of biostatistics and data sciences at Boehringer Ingelheim, said: “Boehringer Ingelheim creates therapeutic value through continuous innovation, so fortifying our R&D efforts with smart, agile technology is vital to our continued success.
“Medidata’s platform of cloud-based solutions and data analytics will increase the efficiency of our R&D and help us be more nimble in developing and conducting increasingly complex clinical trials.
“Ultimately, this can bring new medicines to patients sooner, which is what our team is working to do every day.”
As part of the Medidata Clinical Cloud platform both Celgene and Boehringer Ingelheim will be using:
- Medidata Rave a solution for electronic data capture, management and reporting
- Medidata Designer for study and protocol design
- Medidata Grants Manager for site budgeting and planning
- Safety Gateway for safety reporting
- Medidata Insights, which provides advanced metrics, visualisations and industry data and benchmarks.
Celgene is also leveraging one of Medidata’s turnkey clinical analytics offerings.
Glen de Vries, Medidata’s president, said: “Drug development is becoming more complex by the day, with researchers exploring vast genomes and proteomes increasing prospects to control or cure disease through precision medicine.
“Medidata is providing Celgene and a rapidly growing list of other global life sciences companies with an integrated platform and the fundamental analytics and tools needed to optimise drug development programs.”
Medidata’s chief executive officer Tarek Sherif, said: “Boehringer Ingelheim is committed to a faster and more flexible approach to R&D and Medidata is excited to be a key partner in that effort for years to come.
“Our cloud technology and data-driven analytics deliver the features, the scale and the precise insights that Boehringer Ingelheim and a rapidly growing list of other global pharma companies need to develop exciting medical advances to improve people’s health and transform their lives.”